Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases. Founded by Arthur Weiss, John Kuriyan, and Michael Rape in 2009, Nurix is backed by investors that include Redmile Group, Foresite Capital, Third Rock Ventures, Wellington Management, and EcoR1 Capital and is headquartered in San Francisco.